Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York

Perlmutter Cancer Center at NYU Langone Hospital - Long Island is a clinical research site located in Mineola, New York, United States 11501.

Crixeo Health Trust Score: 80/100 (GOOD). This profile has not yet been claimed by the site owner.

Perlmutter Cancer Center at NYU Langone Hospital - Long Island has participated in 19 clinical trials with 16 currently active.

Therapeutic areas: Non-Small Cell Lung Cancer, Uterine Neoplasms, Uterine Cervical Neoplasms.

Sponsors: Bristol-Myers Squibb, Seagen, a wholly owned subsidiary of Pfizer, Eli Lilly and Company.

Sponsor Feasibility Report

Trust Score: 80/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Perlmutter Cancer Center at NYU Langone Hospital - Long Island?

Perlmutter Cancer Center at NYU Langone Hospital - Long Island has a Crixeo Trust Score of 80/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Perlmutter Cancer Center at NYU Langone Hospital - Long Island conducted?

Perlmutter Cancer Center at NYU Langone Hospital - Long Island has 19 clinical trials on record, with 16 currently active. Their work covers Non-Small Cell Lung Cancer, Uterine Neoplasms, Uterine Cervical Neoplasms.

Is Perlmutter Cancer Center at NYU Langone Hospital - Long Island accredited by Crixeo Health?

Yes — Perlmutter Cancer Center at NYU Langone Hospital - Long Island holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Perlmutter Cancer Center at NYU Langone Hospital - Long Island?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.